European Journal of Hematology
Volume 98, Issue 5, May 2017, Pages 443–44
Xavier Cahu, Martin Carré, Christian Recher, Arnaud Pigneux, Mathilde Hunault-Berger, Norbert Vey, Patrice Chevallier, Jacques Delaunay, Emmanuel Gyan, Bruno Lioure, Caroline Bonmati, Chantal Himberlin, Yosr Hicheri, Gaelle Guillerm, Bouscary Didier, Fabrice Larosa,
Mario Ojeda-Uribe, Marc Bernard, Marie C. Bene, Norbert Ifrah, Jean-Yves Cahn
Abstract
Objectives
Anthracyclines and cytarabine are cornerstones for intensive chemotherapy in acute myeloid leukemia (AML). The goals of this study were to comprehensively assess deviations from theoretical doses and the impact of body-surface area (BSA) on patients’ characteristics, physicians’ strategy, dose adjustment, and clinical outcome.
Methods
The GOELAMS 2001 phase III trial included 823 AML patients below 60 years of age. In the course of treatment, anthropomorphic parameters and chemotherapy doses were prospectively registered.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.